Skip to Content
  • A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I… Read More
  • Antibiotics Are Hard, Continued

    I wrote here about an ingenious synthetic effort into structurally diverse ketolide antibiotics, structures that need a lot of work to make them from the ground… Read More
  • Revusiran’s Failure Revisited

    I wrote about Alnylam’s recent clinical disaster here, where they had to stop a Phase III siRNA therapy trial against a rare amyloidosis with cardiac com… Read More
  • Alnylam Blindsided

    Alnylam, the big name in RNAi therapeutics, had an awful day of it yesterday, and is having another one today. More may be on the way. Rivusiran, their Phase II… Read More
  • Valeant Sure Picks the Winners

    You may remember brodulamab, the anti-IL-17-receptor antibody (update: fixed a mistake in the mechanism) that was under development by Amgen and AstraZeneca for… Read More
  • Glyphosate And Cancer

    Glyphosate (often known by its original brand name, Roundup) is the most widely used agricultural chemical in the world. What, if anything, is it doing to peopl… Read More
Page 1 of 1812345...10...Last »